TNFSF13B and systemic lupus erythematosus: One clinical study comes to a conclusion that combined B cell targeted therapy with rituximab (RTX; anti‐CD20) and belimumab (BLM; anti‐BAFF) prevented full B cell repopulation including double negative B cells, with concomitant specific reduction of SLE‐relevant autoantibodies.41